The Readout Loud

Een podcast door STAT - Donderdagen

Probeer Podimo de eerste 30! dagen gratis

Luister 30 dagen gratis naar exclusieve podcasts en duizenden luisterboeken

350 Afleveringen

346: Zealand's obesity strategy and Immunovant's curious development plan
Gepubliceerd: 20-3-2025
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
Gepubliceerd: 13-3-2025
344: Trump's FDA commissioner nominee takes the hot seat
Gepubliceerd: 6-3-2025
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Gepubliceerd: 27-2-2025
342: FDA cuts, zombie biotechs, and too much weight loss?
Gepubliceerd: 20-2-2025
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Gepubliceerd: 13-2-2025
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
Gepubliceerd: 6-2-2025
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Gepubliceerd: 30-1-2025
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
Gepubliceerd: 23-1-2025
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
Gepubliceerd: 15-1-2025
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
Gepubliceerd: 9-1-2025
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
Gepubliceerd: 19-12-2024
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Gepubliceerd: 12-12-2024
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Gepubliceerd: 5-12-2024
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Gepubliceerd: 21-11-2024
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Gepubliceerd: 14-11-2024
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Gepubliceerd: 7-11-2024
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Gepubliceerd: 31-10-2024
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Gepubliceerd: 24-10-2024
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Gepubliceerd: 17-10-2024

1 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site

350 Afleveringen

346: Zealand's obesity strategy and Immunovant's curious development plan

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

344: Trump's FDA commissioner nominee takes the hot seat

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

342: FDA cuts, zombie biotechs, and too much weight loss?

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

338: Chinese biotechs, a WHO departure, and post-JPM thoughts

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

333: An H5N1 bird flu update and talent scarcity in the radiopharma field

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights